Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24345594 | 0.83 | MAP3K14 (0.45) | MAP3K14ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL16396399 | 0.83 | MAP3K14 (0.49) | MAP3K14ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL10036720 | 0.79 | TERT (0.36) | TERTAHRALOX15ALOX12ADRA2A | |
| SCHEMBL10036710 | 0.79 | TERT (0.36) | TERTAHRALOX15ALOX12ADRA2A | |
| Hydrochloric Acid SCHEMBL2171764 | 0.77 | TERT (0.35) | TERTAHRADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL29200781 | 0.77 | TERT (0.35) | TERTAHRADRA2AADRA2BADRA2C | |
| SCHEMBL25166562 | 0.75 | ADRA2A (0.50) | MAP3K14ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL31347583 | 0.74 | ADRA2A (0.40) | MAP3K14ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL1271967 | 0.71 | MAP3K14 (0.51) | MAP3K14AHRADRA2AHTR1ACYP2D6 | |
| SCHEMBL14904042 | 0.71 | TERT (0.32) | TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601193-B1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM | ELANCO ANIMAL HEALTH IRELAND (IE) | 2015-03-11 | — | — | EP | disclosed |
| EP-2091536-B1 | ENANTIOMERIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | CRESTONE INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130109694-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109694-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2012017030-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM | ELANCO ANIMAL HEALTH IRELAND LIMITED (IE) | 2012-02-09 | — | — | WO | disclosed |
| US-7973050-B2 | 5-[3-((R)(-)-5,7-Dibromo-1,2,3,4-tetrahydro-naphthalen-1-ylamino)-propylamino]-4H-thieno[3,2-b]pyridine-7-one; optically active; new target antibiotic, inhibitor of bacterial methionyl tRNA synthetase; antibiotic resistance; Clostridium difficile infection; mostly in immunodeficient, elderly | CRESTONE, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2091536-A2 | ENANTIOMERIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Crestone, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20080108651-A1 | Enantiomeric Compounds With Antibacterial Activity | REPLIDYNE, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| WO-2008039640-A2 | ENANTIOMERIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | CRESTONE, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109694-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM | VIP, PRF1, C5 | MAP3K14 2628/4885TERT 4725/4885AHR 4330/4885 |
| US-20080108651-A1 | Enantiomeric Compounds With Antibacterial Activity | MTR, HMBS, MAT1A | MAP3K14 4467/4885TERT 3075/4885AHR 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.